<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00625729</url>
  </required_header>
  <id_info>
    <org_study_id>2007LS064</org_study_id>
    <secondary_id>MT2007-12</secondary_id>
    <secondary_id>UMN-0707M13561</secondary_id>
    <secondary_id>P01CA065493</secondary_id>
    <nct_id>NCT00625729</nct_id>
  </id_info>
  <brief_title>Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>MT2007-12 Allogeneic Natural Killer Cells With Rituximab in Patients With CD20 Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia. Strategies to Increase Sensitivity of CLL Tumor Cells to Natural Killer Cell-Immune-Mediated Cytolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating
      natural killer cells with aldesleukin in the laboratory may help the natural killer cells
      kill more cancer cells when they are put back in the body. Giving monoclonal antibodies, such
      as rituximab, and chemotherapy drugs, such as fludarabine and cyclophosphamide, before a
      donor natural killer cell infusion helps stop the growth of cancer cells. It also helps stop
      the patient's immune system from rejecting the donor's stem cells.

      PURPOSE: This phase I/II trial is studying how well giving rituximab and chemotherapy
      followed by a donor natural killer cell infusion that has been treated in the laboratory with
      aldesleukin followed by aldesleukin works in treating patients with non-Hodgkin lymphoma or
      chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine if allogeneic natural killer (NK) cells infused following
           chemoimmunotherapy can be safely expanded in vivo with aldesleukin.

      Secondary

        -  To determine if interleukin-15 production at day 0 correlates with NK cells expansion.

        -  To determine overall response rate at 3 months.

        -  To determine time to progression and overall survival.

        -  To characterize the quantitative and qualitative toxicities of this treatment plan.

        -  To determine the incidence of donor products that do not meet release criteria and the
           NK cell numbers infused.

        -  To correlate clinical response with donor/recipient KIR ligand matching status, FcG
           receptor 3A genotype, and NK cells phenotype and function

        -  To determine pharmacodynamic and pharmacogenomic markers and correlate them with NK cell
           expansion and disease response.

      OUTLINE:

        -  Conditioning regimen: Patients receive rituximab intravenously (IV) over 6-8 hours on
           days -8, -1, 6, and 13; fludarabine IV on days -6 to -2; and cyclophosphamide IV on day
           -5.

        -  Allogeneic natural killer (NK) cell administration: Patients receive
           aldesleukin-activated haploidentical NK cells IV over less than 1 hour on day 0. Within
           4 hours after allogeneic NK cell infusion, patients receive aldesleukin subcutaneously
           (SC) 3 times a week for 6 doses. Patients also receive filgrastim (G-CSF) SC beginning
           on day 14 and continuing until absolute neutrophil count (ANC) is &gt; 2,500/mm³ for 2
           consecutive days.

      Patients who achieve a complete or partial response at 28 days are eligible for allogeneic
      stem cell transplantation. Patients who achieve initial response at 3 months, clinically
      benefit from treatment, but subsequently relapse are eligible for retreatment provided all
      eligibility criteria are met.

      Blood samples are collected periodically for correlative laboratory studies. Patients with
      chronic lymphocytic leukemia (CLL) also undergo bone marrow aspiration periodically for
      correlative laboratory studies.

      After completion of study treatment, patients are followed periodically for up to 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No patients exhibited natural killer cell expansion (primary endpoint).
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Exhibiting Natural Killer Cell Expansion</measure>
    <time_frame>Day 14</time_frame>
    <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Interleukin-15 Production and NK Cell Expansion</measure>
    <time_frame>Day 0</time_frame>
    <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Overall Response</measure>
    <time_frame>3 Months</time_frame>
    <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Whose Disease Progressed After Treatment</measure>
    <time_frame>6 Months</time_frame>
    <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adequate Natural Killer Cells Infused</measure>
    <time_frame>Day 0</time_frame>
    <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Overall Survival</measure>
    <time_frame>6 Months</time_frame>
    <description>Number of patients alive at 6 months after treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treated Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Day 0-14, 10 million international units, 3 times per week for 6 doses</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic natural killer cells</intervention_name>
    <description>Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Natural Killer Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>60 mg/kg intravenous (IV) on Day -5.</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Day -6 through day -2, 25 mg/m^2 intravenous (IV)</description>
    <arm_group_label>Treated Patients</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years or older with a diagnosis of non-Hodgkin Lymphoma or chronic
             lymphocytic leukemia (NHL or CLL) and one of the following:

               -  Progression of NHL following at least 2 prior chemotherapy regimens, (must
                  contain rituximab for all NHL and fludarabine for follicular NHL) defined as:

                    -  failure to achieve partial remission (PR) with the last chemotherapy

                    -  disease progression within 6 months following last chemotherapy

               -  Progression of CLL/SLL (small lymphocytic lymphoma) following at least 2 prior
                  chemotherapy regimens (containing purine analogs ) in stage Rai III or IV or
                  symptomatic disease.

               -  Relapsed NHL or CLL following stem cell transplantation for whom the option of
                  donor lymphocyte infusion is not available or clinically indicated (e.g.
                  recipients of autologous or umbilical cord blood [UCB] transplants).

          -  Available related HLA-haploidentical (human leukocyte antigen) natural killer (NK)
             cell adult donor by at least Class I serologic typing

          -  Karnofsky performance status &gt; 60%

          -  Measurable disease based on modified Response Evaluation Criteria In Solid Tumors
             (RECIST)

          -  Have acceptable organ function as defined within 28 days of enrollment:

               -  Hematologic: platelets ≥ 80,000 x 10^9/L; hemoglobin ≥ 9g/dL, unsupported by
                  transfusions; absolute neutrophil count (ANC) ≥ 1000 x 10^9/L, unsupported by
                  granulocyte-colony stimulating factor or granulocyte-macrophage
                  colony-stimulating factor (G-CSF or GM-CS)F for 10 days or Neulasta for 21 days -
                  the hematologic requirements are waived for patients with inadequate counts due
                  to known bone marrow involvement by lymphoma who are otherwise eligible

               -  Renal: glomerular filtration rate (GFR) &gt; 50 ml/min

               -  Hepatic: alanine aminotransferase (ALT), aspartate aminotransferase (AST) &lt; 3 x
                  upper limit of normal and total bilirubin &lt;3 mg/dl

               -  Pulmonary function: &gt;50% corrected carbon monoxide diffusing capacity (DLCO) and
                  Forced Expiratory Volume in the first second (FEV1)

               -  Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection
                  fraction &gt;40%

          -  Off prednisone or other immunosuppressive medications for at least 3 days prior to Day
             0

          -  Women of childbearing potential must agree to use adequate contraception (diaphragm,
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,
             subcutaneous implants, or abstinence, etc.) for the duration of treatment.

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care.

        Exclusion Criteria:

          -  Pregnant or lactating. The agents used in this study may be teratogenic to a fetus and
             there is no information on the excretion of agents into breast milk. All females of
             childbearing potential must have a blood test or urine study within 2 weeks prior to
             registration to rule out pregnancy. Women of childbearing age must use appropriate
             contraceptive method.

          -  Active central nervous system (CNS) lymphoma/leukemia

          -  Active serious infection (pulmonary infiltrates or lesions are allowed only after the
             appropriate diagnostic testing is negative for infection or appropriate therapy was
             initiated for probable infection)

          -  Pleural effusion - large enough to be detectable on the chest x-ray

          -  Allergy to rituximab or IL-2

          -  Human immunodeficiency virus (HIV) and associated non-Hodgkins lymphoma (NHL)

          -  Active concurrent malignancy (except skin cancer) requiring systemic therapy in the
             past 2 years

          -  Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder

          -  Positive hepatitis B surface antigen (HBsAg). If Hepatitis B core antibody (HBcAb) is
             positive, Hepatitis B deoxyribonucleic acid (DNA) by polymerase chain reaction (PCR)
             will be evaluated. Positive anti HBcAb and undetectable viral load does not exclude
             the patient.

          -  Any experimental therapy in the past 30 days

        Donor Selection:

          -  Related donors (sibling, parent, offspring, parent or offspring of an HLA identical
             sibling) ≥ age 18 years

          -  Able and willing to undergo lymphapheresis

          -  HLA-haploidentical donor/recipient match. If time permits and multiple donors are
             available, preference will be given to the Killer-cell Immunoglobulin-like Receptors
             (KIR) ligand mismatched donor (as predicted by HLA typing).

          -  HIV-1, HIV-2 negative, Human T-lymphotropic virus Type I (HTLV-1), HTLV-2 negative,
             West Nile virus (WNV) negative, Hepatitis B and C negative

          -  Adequate organ function defined as:

               -  Hematologic: CBC/diff/platelet count near normal limits,

               -  Hepatic: ALT &lt; 2 x upper limit of normal,

          -  Not pregnant or lactating

          -  In general good health as determined by the study physician

          -  Able to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronika Bachanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2008</study_first_posted>
  <results_first_submitted>July 2, 2010</results_first_submitted>
  <results_first_submitted_qc>July 2, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2010</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Exhibiting Natural Killer Cell Expansion</title>
        <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Exhibiting Natural Killer Cell Expansion</title>
          <description>Successful natural killer (NK) cell expansion will be defined as an absolute circulating donor-derived NK cell count of &gt;100 cells/μl 14 days after infusion with &lt;5% donor T and B cells in the mononuclear population.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Interleukin-15 Production and NK Cell Expansion</title>
        <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
        <time_frame>Day 0</time_frame>
        <population>Correlation of interleukin-15 with Natural Killer Cell expansion cannot be calculated because there was no Natural Killer Cell expansion.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Interleukin-15 Production and NK Cell Expansion</title>
          <description>Correlation of interleukin-15 production at day 0 with natural killer (NK) cells expansion</description>
          <population>Correlation of interleukin-15 with Natural Killer Cell expansion cannot be calculated because there was no Natural Killer Cell expansion.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Overall Response</title>
        <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Overall Response</title>
          <description>Overall response (complete remission plus partial remission) rate at 3 months, as defined by International Working Group for non-Hodgkin lymphoma and NCI Working Group guidelines for chronic lymphocytic leukemia</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Whose Disease Progressed After Treatment</title>
        <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
        <time_frame>6 Months</time_frame>
        <population>Only patients who responded to treatment included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Responder Patients</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy who had a response to treatment (clinical response or partial response).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Whose Disease Progressed After Treatment</title>
          <description>Includes patients (with non-Hodgkin leukemia or chronic lymphocytic leukemia) whose disease progressed after treatment.</description>
          <population>Only patients who responded to treatment included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adequate Natural Killer Cells Infused</title>
        <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
        <time_frame>Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adequate Natural Killer Cells Infused</title>
          <description>Incidence of donor products that met release criteria in accordance with FDA regulations (Lot Release Criteria for allogeneic, interleukin-2 (IL-2) activated natural killer (NK) cell products (BB-IND 8847) and the NK cell numbers infused (donor NK cell dose 1.5-8.0 x 10^7/kg).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Overall Survival</title>
        <description>Number of patients alive at 6 months after treatment.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients Treated With Natural Killer Cells</title>
            <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Overall Survival</title>
          <description>Number of patients alive at 6 months after treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events were collected after start of chemotherapy treatment (Day -1) through date of death (all within 6 months).</time_frame>
      <desc>Stopping Rules for excess toxicity:
Any non-hematologic grade 4 toxicity except for fevers alone
Grade III/IV GvHD or GvHD requiring more than 7 days of therapy
Hematologic toxicity: prolonged neutropenia defined as an absolute neutrophil count of less than 500 on day +35. Prolonged anemia or thrombocytopenia will not constitute toxicity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Patients Treated With Natural Killer Cells</title>
          <description>Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with 1 dose donor natural killer cells infusion, 4 doses rituximab, 6 doses aldesleukin and 5 doses fludarabine and 1 dose cyclosphosphamide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>ANC &lt;500 at day +35</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <description>Ventricular arrhythmia - Bigeminy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - Disease Progression NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary - obstruction/stenosis of airway</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated early due to lack of NK expansion and failure to meet primary outcome.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Veronika Bachanova, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-5469</phone>
      <email>bach0173@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

